CD7 CAR-T Cell Therapy Targeting CD7-positive Relapsed/Refractory T Cell Lymphoma/Acute Leukemia

NCT07008872 · clinicaltrials.gov ↗

NA

Phase

NOT_YET_RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

CD7+ Lymphoma
CD7+ Acute Leukemia

Interventions

BIOLOGICAL: CD7 CART

Sponsor

Qi deng

Collaborators

[object Object]